Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>ABSTRACT</jats:title><jats:p>The<jats:italic>bla</jats:italic><jats:sub>IMP-14</jats:sub>carbapenem resistance gene has largely previously been observed in<jats:named-content xmlns:xlink="http://www.w3.org/1999/xlink" content-type="genus-species" xlink:type="simple">Pseudomonas aeruginosa</jats:named-content>and<jats:named-content xmlns:xlink="http://www.w3.org/1999/xlink" content-type="genus-species" xlink:type="simple">Acinetobacter</jats:named-content>spp. As part of global surveillance and sequencing of carbapenem-resistant<jats:named-content xmlns:xlink="http://www.w3.org/1999/xlink" content-type="genus-species" xlink:type="simple">Escherichia coli</jats:named-content>, we identified a sequence type 131 strain harboring<jats:italic>bla</jats:italic><jats:sub>IMP-14</jats:sub>within a class 1 integron, itself nested within an ∼54-kb multidrug resistance region on an epidemic IncA/C<jats:sub>2</jats:sub>plasmid. The emergence of<jats:italic>bla</jats:italic><jats:sub>IMP-14</jats:sub>in this context in the ST131 lineage is of potential clinical concern.</jats:p>

Original publication

DOI

10.1128/aac.00840-16

Type

Journal article

Journal

Antimicrobial Agents and Chemotherapy

Publisher

American Society for Microbiology

Publication Date

08/2016

Volume

60

Pages

5068 - 5071